Hu3F8
Drug timelines are a Plus or Pro feature.
4 regulatory and trial events tracked for Hu3F8, covering 2025-07-30 to 2026-01-07. Get the full timeline:
Most recent: Clinical Trial Update: Combination Therapy of Antibody Hu3F8 With Granulocyte- Macrophage Colony Stimulating Factor (GM-CSF) in Patients With Relapsed/Refractory High-Risk Neuroblastoma [Phase 1, Phase 2]